SCHWIND AMARIS准分子激光联合丝裂霉素C行LASEK术矫治远视的研究(英文)

LASER for the correction of hyperopia with mitomycin C using SCHWIND AMARIS excimer laser:one-year follow-up

目的：评估SCHWIND AMARIS准分子激光在LASEK术中矫治远视手术中的有效性,安全性和可预测性。方法：回顾性研究LASEK术联合使用丝裂霉素C矫治远视患者33例66眼,平均年龄35.42±1.12岁（范围18~56a）。每位患者予SCHWIND AMARIS准分子激光行LASEK术。术后对其可预测性、安全性、有效性及主观验光情况进行评估,并分析客观验光、裸眼视力、最佳矫正视力及不良反应。结果：平均屈光度为3.2±1.6D（0~7D）,术前及术后平均等效球镜分别为2.34±1.76D（-1.25~7D）及0.30±0.84D（-0.2~0.8D）（P=0.001）。术后6~12mo,平均远视为0.63±0.84D（-1.75~2.76D）。平均散光度为0.68±0.43D（0~2D）,61眼（78.2%）和31眼（39.7%）散光度分别在±1D和±0.50D范围内。安全指数和有效性指数分别为1.08和1.6。结论：应用SCHWIND AMARIS准分子激光联合丝裂霉素C行LASEK术矫治远视具有良好的视觉和屈光结果,而且无严重并发症。

AIM：To evaluate the efficacy,safety and predictability of laser-assisted sub-epithelial keratectomy（LASEK） for the correction of hyperopia using the SCHWIND AMARIS platform.METHODS：This retrospective single-surgeon study includes 66 eyes of 33 patients with hyperopia who underwent LASEK with mitomycin C（MMC）.The median age of patients was 35.42±1.12y（ranging 18 to 56y）.In each patient LASEK was performed using SCHWIND AMARIS excimer laser.Postoperatively clinical outcomes were evaluated in terms of predictability,safety,efficacy,subjective and objective refractions,uncorrected visual acuity（UCVA）,best spectacle-corrected visual acuity（BSCVA） and adverse events.RESULTS：The mean baseline refraction was 3.2±1.6diopters（D）（ranging 0 to 7 D）.The mean pre-operative and postoperative spherical equivalent（SE） were 2.34±1.76（ranging-1.25 to 7 D） and 0.30±0.84（ranging-0.2to 0.8 D） respectively（P=0.001）.The mean hyperopia was 0.63±0.84 D（ranging-1.75 to 2.76 D） 6 to 12 mo postoperatively.Likewise,the mean astigmatism was0.68±0.43 D（range 0 to 2 D） with 51（77.3%） and 15（22.7%） eyes within ±1 and ±0.50 D respectively.The safety index and efficacy index were 1.08 and 1.6respectively.. CONCLUSION：LASEK using SCHWIND AMARIS with MMC yields good visual and refractive results for hyperopia.Moreover,there were no serious complications.